Natriuretic Peptides, Inflammation, and Sounding the Alarm.
作者信息
Ramakrishnan Vijay, Burnett John C
机构信息
Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (V.R., J.C.B.), Mayo Clinic, Rochester, MN.
Division of Hematology (V.R.), Mayo Clinic, Rochester, MN.
出版信息
Circ Heart Fail. 2020 Jul;13(7):e007208. doi: 10.1161/CIRCHEARTFAILURE.120.007208. Epub 2020 Jul 2.
Abstract
摘要
相似文献
1
Natriuretic Peptides, Inflammation, and Sounding the Alarm.利钠肽、炎症与发出警报
Circ Heart Fail. 2020 Jul;13(7):e007208. doi: 10.1161/CIRCHEARTFAILURE.120.007208. Epub 2020 Jul 2.
2
Natriuretic Peptide Guidance for Post-Myocardial Infarction Care: An Opportunity to Prevent Heart Failure Progression.利钠肽指导心肌梗死后护理：预防心力衰竭进展的契机
Circ Heart Fail. 2023 May;16(5):e010540. doi: 10.1161/CIRCHEARTFAILURE.123.010540. Epub 2023 May 1.
3
Natriuretic peptides in diagnostics and therapy.利钠肽在诊断与治疗中的应用。
Pol Merkur Lekarski. 2020 Oct 23;48(287):370-374.
4
Natriuretic Peptide Measurement Is Key to a Solution in the Clinical Trial and Clinical Practice.利钠肽测量是临床试验和临床实践中解决问题的关键。
JACC Heart Fail. 2020 Sep;8(9):782-783. doi: 10.1016/j.jchf.2020.06.011.
5
Reply: Natriuretic Peptide Measurement Is Key to a Solution in the Clinical Trial and Clinical Practice.回复：利钠肽检测是临床试验和临床实践中解决问题的关键。
JACC Heart Fail. 2020 Sep;8(9):783-784. doi: 10.1016/j.jchf.2020.07.001.
6
[Natriuretic peptides as prognosticators in congestive heart failure].[利钠肽作为充血性心力衰竭的预后指标]
Arq Bras Cardiol. 2006 Aug;87(2):73-4. doi: 10.1590/s0066-782x2006001500002.
7
Natriuretic peptides: novel therapeutic targets in heart failure.利钠肽：心力衰竭中的新型治疗靶点。
J Investig Med. 2005 Nov;53(7):378-84. doi: 10.2310/6650.2005.53711.
8
Natriuretic Peptides in Clinical Practice.临床实践中的利钠肽
Anatol J Cardiol. 2019 Mar;21(Suppl 1):1-40. doi: 10.14744/AnatolJCardiol.2019.55623.
9
Natriuretic peptides in the diagnosis and management of acute heart failure.利钠肽在急性心力衰竭的诊断与管理中的应用
Heart Fail Clin. 2009 Oct;5(4):489-500. doi: 10.1016/j.hfc.2009.04.007.
10
Cardiac natriuretic peptides in heart failure.心力衰竭中的心脏利钠肽
Ann Med. 1993 Dec;25(6):503-5.
引用本文的文献
1
Clinical Insights from Proteomics in Heart Failure.心力衰竭蛋白质组学的临床见解
Curr Heart Fail Rep. 2025 Mar 10;22(1):12. doi: 10.1007/s11897-025-00698-w.
2
The Different Paths That Lead to Hypotonic Hyponatremia, and a Safe Approach to Treatment.导致低渗性低钠血症的不同途径及安全的治疗方法。
J Clin Med. 2024 Dec 27;14(1):92. doi: 10.3390/jcm14010092.
3
Association between Inflammation and New-Onset Atrial Fibrillation in Acute Coronary Syndromes.急性冠脉综合征中炎症与新发心房颤动之间的关联
J Clin Med. 2024 Aug 27;13(17):5088. doi: 10.3390/jcm13175088.
4
When the liver is in poor condition, so is the heart - cardiac remodelling in MASH mouse models.肝脏不好，心脏也好不到哪里去——MASH 小鼠模型中的心脏重构。
Clin Sci (Lond). 2024 Sep 18;138(18):1151-1171. doi: 10.1042/CS20240833.
5
PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response.氯贝丁酯激活过氧化物酶体增殖物激活受体-α可减轻代谢综合征大鼠缺血/再灌注损伤，其机制可能与减轻心肌炎症和重构以及调节心钠肽代偿反应有关。
Int J Mol Sci. 2023 Mar 10;24(6):5321. doi: 10.3390/ijms24065321.
6
Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension.内皮素 B 受体在肺动脉高压中的免疫动力学。
Front Immunol. 2022 Jun 9;13:895501. doi: 10.3389/fimmu.2022.895501. eCollection 2022.
7
Corin: A Key Mediator in Sodium Homeostasis, Vascular Remodeling, and Heart Failure.Corin：钠稳态、血管重塑和心力衰竭中的关键介质
Biology (Basel). 2022 May 7;11(5):717. doi: 10.3390/biology11050717.
8
Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis.抗风湿治疗与自身免疫性关节炎患者循环 N 端脑利钠肽前体水平的变化无关。
PLoS One. 2021 Jun 25;16(6):e0253793. doi: 10.1371/journal.pone.0253793. eCollection 2021.
本文引用的文献
1
Inflammation and Circulating Natriuretic Peptide Levels.炎症与循环利钠肽水平。
Circ Heart Fail. 2020 Jul;13(7):e006570. doi: 10.1161/CIRCHEARTFAILURE.119.006570. Epub 2020 Jun 8.
2
Prognostic value of NT-proBNP in patients with severe COVID-19.NT-proBNP 对重症 COVID-19 患者的预后价值。
Respir Res. 2020 Apr 15;21(1):83. doi: 10.1186/s12931-020-01352-w.
3
Atrial Natriuretic Peptide, Heart Failure and the Heart as an Endocrine Organ.心房利钠肽、心力衰竭与作为内分泌器官的心脏
Clin Chem. 2019 Dec;65(12):1602-1603. doi: 10.1373/clinchem.2019.308106. Epub 2019 Jul 30.
4
C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts.C53：一种新型的颗粒型鸟苷酸环化酶 B 受体激动剂，在体内具有持续的活性，并对人心脏和肾成纤维细胞具有抗纤维化作用。
J Mol Cell Cardiol. 2019 May;130:140-150. doi: 10.1016/j.yjmcc.2019.03.024. Epub 2019 Apr 4.
5
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.破坏自我放大儿茶酚胺循环可减少细胞因子释放综合征。
Nature. 2018 Dec;564(7735):273-277. doi: 10.1038/s41586-018-0774-y. Epub 2018 Dec 12.
6
N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study.急诊科 N 末端 B 型利钠肽原：ICON-RELOADED 研究。
J Am Coll Cardiol. 2018 Mar 20;71(11):1191-1200. doi: 10.1016/j.jacc.2018.01.021.
7
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
8
Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling.实验性心力衰竭伴心房重构时肾脏中有害分子途径的早期激活。
Physiol Rep. 2017 May;5(9). doi: 10.14814/phy2.13283. Epub 2017 May 15.
9
Molecular Physiology of Membrane Guanylyl Cyclase Receptors.膜鸟苷酸环化酶受体的分子生理学
Physiol Rev. 2016 Apr;96(2):751-804. doi: 10.1152/physrev.00022.2015.
10
Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study.利钠肽水平的种族差异：达拉斯心脏研究
JACC Heart Fail. 2015 Jul;3(7):513-519. doi: 10.1016/j.jchf.2015.02.008. Epub 2015 Jun 10.
Zotero 插件